MedTrace Logo

A Study of Danning Tablet in Patients With Polypoid Lesions of Gallbladder

NCT05668871 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2022-12-30

No results posted yet for this study

Summary

The primary goal of this clinical trial is to evaluate the effect of Danning Tablet on shrinkage of gallbladder polyps compared to lifestyle intervention in 336 patients with gallbladder polyps. The main questions it aims to answer are:

* Medicine may be effective on shrinkage of gallbladder polyps and alleviation of clinical symptoms of gallbladder polyps.
* Chinese patent medicine (herbal medicine) may be safety in treatment of gallbladder polyps.

Conditions

  • Polyps Gallbladder

Interventions

DRUG

Danning Tablet

3 times each day, 5 tablets each time, take orally after meals.

Sponsors & Collaborators

  • Eastern Hepatobiliary Surgery Hospital

    lead OTHER

Principal Investigators

  • Feng Shen, MD, PhD · Eastern Hepatobiliary Surgery Hospital, Naval Medical University

  • Tian Yang, MD, PhD · Eastern Hepatobiliary Surgery Hospital, Naval Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-08-31
Completion
2024-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05668871 on ClinicalTrials.gov